09 September 2002
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations
Marina Núńez, Carmen de Mendoza, Luisa Valer, Esperanza Casas, Soledad López-Calvo, Ángeles Castro, Beatriz Rosón, Daniel Podzamczer, Amalia Rubio, Juan Berenguer, Vincent SorianoMed Sci Monit 2002; 8(9): CR620-623 :: ID: 13277
Abstract
Summary
Background: The purpose of our study was to assess the presence of nelfinavir (NFV)-associated resistance mutations at the time of early virological failure in subjects receiving NFV as part of a first protease inhibitor (PI)-based triple regimen.
Material/Methods: Subjects failing their first PI-based NFV-containing triple regimen were identified in six Spanish hospitals. HIV genotyping was carried out in plasma samples collected at the time of
the first viral rebound.
Results: Upon initiation of NFV-based therapy, 19 of the 30 subjects (63%) were naïve; 11 (37%) had been exposed to nucleoside analogues. Median HIV-RNA at the time of viral rebound was 4,
180 copies/ml. PCR-amplified products were obtained in 22 subjects (73%). These products were sequenced and primary PI resistance mutations were recognized in 6 patients (27%). All six individuals harbored the D30N mutation, and none presented the L90M mutation. Other PI resistance mutations were present in 5 subjects (at codons 36, 63, 71, 77, 82 and/or 88). Secondary PI resistance mutations were present in another 9 subjects. By contrast, mutations conferring resistance to reverse transcriptase inhibitors were present in 50% of the patients, and the M184V substitution was the most frequently seen.
Conclusions: Nearly 75% of patients failing their first PI-based triple regimen containing NFV do not harbor PI resistance mutations. The D30N substitution, rather than L90M, is the most frequently
recognized, which does not challenge the efficacy of further rescue interventions with other PIs. This observation supports the use of nelfinavir as first protease inhibitor
Keywords: Drug Resistance, Genes, Viral, Genotype, HIV - genetics, HIV Protease - genetics, HIV Protease Inhibitors - therapeutic use, HIV Seropositivity - drug therapy, HIV-1 Reverse Transcriptase - genetics, Mutation, Nelfinavir - therapeutic use
544 2
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
05 Jun 2023 : Clinical Research
Comparison of Texture and Color Enhancement Imaging with White Light Imaging in 52 Patients with Short-Segm...Med Sci Monit In Press; DOI: 10.12659/MSM.940249
05 Jun 2023 : Laboratory Research
Comparison of Composite Resin (Duo-Shade) Shade Guide with Vita Ceramic Shades Before and After Chemical an...Med Sci Monit In Press; DOI: 10.12659/MSM.940949
02 Jun 2023 : Database Analysis
The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940904
01 Jun 2023 : Clinical Research
Root Canal Numbers and Configurations in 1080 Permanent Canine Teeth in 270 Saudi Subjects Using Cone-Beam ...Med Sci Monit In Press; DOI: 10.12659/MSM.940472
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952